Although Campylobacter jejuni is the pathogen responsible for the most common foodborne illness, tracing of the infection source remains challenging due to its highly variable genome. Therefore, one of the aim of the study was to compare three genotyping methods (MLST, PFGE, and mP-BIT) to determine the most effective genotyping tool. C. jejuni strains were divided into 4 clusters based on strain similarity in the cgMLST dendrogram. Subsequently, the dendrograms of the 3 tested methods were compared to determine the accuracy of each method compared to the reference cgMLST method. Moreover, a cost-benefit analysis has showed that MLST had the highest inverse discrimination index (97%) and required less workflow, time, fewer consumables, and low bacterial sample quantity. PFGE was shown to be obsolete both because of its low discriminatory power and the complexity of the procedure. Similarly, mP‐BIT showed low separation results, which was compensated by its high availability. Therefore, our data showed that MLST is the optimal tool for genotyping C. jejuni. Another aim was to compare the antimicrobial resistance to ciprofloxacin, erythromycin, and tetracycline in C. jejuni strains isolated from human, water, air, food, and animal samples by two gene sequence-based prediction methods and to compare them with the actual susceptibility of C. jejuni strains using the disc diffusion method. Both tools, ResFinder and RGI, synchronously predict the antimicrobial susceptibility of C. jejuni and either can be used.
- MeSH
- antibakteriální látky farmakologie MeSH
- bakteriální léková rezistence genetika MeSH
- Campylobacter jejuni * genetika MeSH
- genotyp MeSH
- kampylobakterové infekce * mikrobiologie MeSH
- lidé MeSH
- mikrobiální testy citlivosti MeSH
- multilokusová sekvenční typizace MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
Microbiota can significantly contribute to colorectal cancer initiation and development. It was described that E. coli harbouring polyketide synthase (pks) genes can synthetize bacterial toxin colibactin, which was first described by Nougayrede's group in 2006. E. coli positive for pks genes were overrepresented in colorectal cancer biopsies and, therefore, prevalence and the effect of pks positive bacteria as a risk factor in colorectal cancer development is in our interest. Interestingly, pks gene cluster in E. coli shares a striking 100% sequence identity with K. pneumoniae, suggesting that their function and regulation are conserved. Moreover, K. pneumoniae can express a variety of virulence factors, including capsules, siderophores, iron-scavenging systems, adhesins and endotoxins. It was reported that pks cluster and thereby colibactin is also related to the hypervirulence of K. pneumoniae. Acquisition of the pks locus is associated with K. pneumoniae gut colonisation and mucosal invasion. Colibactin also increases the likelihood of serious complications of bacterial infections, such as development of meningitis and potentially tumorigenesis. Even though K. pneumoniae is undoubtedly a gut colonizer, the role of pks positive K. pneumoniae in GIT has not yet been investigated. It seems that CRC-distinctive microbiota is already present in the early stages of cancer development and, therefore, microbiome analysis could help to discover the early stages of cancer, which are crucial for effectiveness of anticancer therapy. We hypothesize, that pks positive K. pneumoniae can be a potential biomarker of tumour prevalence and anticancer therapy response.
Závěrečná zpráva o řešení grantu Interní grantové agentury MZ ČR
30 l. : il., tab. ; 31 cm
Porušení signálních drah JAK/STAT a jejich inhibitorů může být příčinou selhání imunitního dozoru a může napomáhat při vzniku a šíření různých nádorů, včetně karcinomů prostaty, mléčné žlázy a astrogliálních nádorů. Cílem je analýza exprese proteinů rodiny STAT,JAK a jejich inhibitorů SOCS u nádorů mozku, mléčné žlázy a prostaty a jejich korelace s proliferační aktivitou, gradingem a expresí hormonálních receptorů či proteinů regulujících apoptózu a buněčný cyklus. Předpokládáme identifikaci nových prognostických a prediktivních znaků u nádorů mozku, mléčné žlázy a prostaty.; Disruption of signaling of JAK/STAT/SOCS may be the cause of failure of immune surveillance and may participate in development and invasion of various tumors, including carcinomas of prostate gland, breast and glial tumors of brain. The aim is analysis of expression of proteins JAK/STAT/SOCS in carcinomas of prostate gland, breast and in gliomas and its correlation with grading, expression of steroid receptors and proteins regulating apoptosis, proliferation and cell cycle. We suppose identification ofnew prognostic and predictive markers in glial tumors of brain and in carcinomas of breast and prostate gland.
- MeSH
- cellular apoptosis susceptibility protein MeSH
- nádory mozku MeSH
- nádory prostaty MeSH
- nádory prsu MeSH
- prognóza MeSH
- proteiny buněčného cyklu MeSH
- steroidní receptory MeSH
- transkripční faktory MeSH
- Konspekt
- Biochemie. Molekulární biologie. Biofyzika
- NLK Obory
- biologie
- onkologie
- NLK Publikační typ
- závěrečné zprávy o řešení grantu IGA MZ ČR
- MeSH
- financování organizované MeSH
- genetické techniky využití MeSH
- glioblastom genetika imunologie MeSH
- imunoblotting metody využití MeSH
- Janus kinasy diagnostické užití genetika MeSH
- lékařská onkologie metody trendy MeSH
- lidé MeSH
- nádorové buněčné linie cytologie imunologie MeSH
- nádory prostaty MeSH
- nádory prsu genetika imunologie MeSH
- PPAR gama diagnostické užití genetika MeSH
- Check Tag
- lidé MeSH
- MeSH
- apoptóza účinky záření MeSH
- finanční podpora výzkumu jako téma MeSH
- hlodavci MeSH
- lidé MeSH
- nádory etiologie terapie MeSH
- přehledová literatura jako téma MeSH
- proliferátory peroxizomů agonisté terapeutické užití MeSH
- receptory cytoplazmatické a nukleární agonisté genetika účinky léků MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- MeSH
- apoptóza MeSH
- buněčný cyklus fyziologie účinky léků MeSH
- finanční podpora výzkumu jako téma MeSH
- glioblastom patologie MeSH
- hypoglykemika farmakologie MeSH
- hypolipidemika farmakologie MeSH
- lidé MeSH
- nádory mozku patologie MeSH
- receptory cytoplazmatické a nukleární agonisté MeSH
- Check Tag
- lidé MeSH
